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Abstract 
 
Based on the MAO inhibition properties of aminoheterocycles with a carbonitrile group we have carried 
out a systematic exploration to discover new classes of carbonitriles endowed with dual MAO and AChE 
inhibitory activities, and Aβ anti-aggregating properties. Eighty-three nitrile-containing compounds, 13 of 
which are new, were synthesized and evaluated. In vitro screening revealed that 31, a new compound, 
presented the best lead for trifunctional inhibition against MAO A (0.34 μM), MAO B (0.26 μM) and AChE 
(52 μM), while 32 exhibited a lead for selective MAO A (0.12 μM) inhibition coupled to AChE (48 μM) 
inhibition. Computational analysis revealed that the malononitrile group can find an advantageous position 
with the aromatic cleft and FAD of MAO A or MAO B.  However, the total binding energy can be 
handicapped by an internal penalty caused by twisting of the ligand molecule and subsequent disruption of 
the conjugation (32 in MAO B compared to the conjugated 31). Conjugation is also important for AChE as 
well as the hydrophilic character of malononitrile that allows this group to be in close contact with the 
aqueous environment as seen for 83.  Although the effect of 31 and 32 against Aβ1-42, was very weak, the 
effect of 63 and 65, and of the new compound 75, indicated that these compounds were able to disaggregate 
Aβ1-42 fibrils. The most effective was 63, a (phenylhydrazinylidene)propanedinitrile derivative that also 
inhibited MAO A (1.65 μM), making it a potential lead for Alzheimer’s disease application. 
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1 INTRODUCTION 
 
Alzheimer`s disease (AD), the most common neurodegenerative disease, is marked by 
progressive decline in a variety of higher cortical functions. AD patients share common 
clinical and neuropathological features, notably intracellular neurofibrillary tangles and 
extracellular senile plaques, the two major pathological hallmarks (Korabecny et al., 
2018). Neurofibrillary tangles are formed by hyperphosphorylated tau protein, while 
senile plaques are aggregates of amyloid β (Aβ) peptides associated with several proteins, 
metal ions, and enlarged axons and synaptic terminals. Moreover, reduced levels of 
acetylcholine (ACh) in specific brain regions that mediate memory and learning 
functions, loss of neurons and synapses, high levels of metal ions like Cu2+, Zn2+, Fe3+, 
mitochondrial dysfunction, inflammation and the associated oxidative stress (OS) 
represent features of this multifactorial disease (Das & Basu, 2017; Jakob-Roetne & 
Jacobsen, 1992). Acetylcholinesterase (AChE) hydrolyzes extracellular ACh into choline 
and acetic acid, thus preventing the overstimulation of nerve cells. However, in AD, loss 
of cholinergic neurons means that stimulation of nerve cells by ACh is reduced, and 
neuronal communication is hindered. AChE inhibitors improve neuronal communication 
by preventing the breakdown of ACh (Das & Basu, 2017).  
Noncatalytic functions of AChE have been suggested in multiple physiological 
processes, such as cell adhesion, neurite growth, apoptosis, and Aβ aggregation (Wang & 
Zhang, 2019). AChE interacts with Aβ by the hydrophobic environment close to the 
peripheral anionic site (PAS) (Johnson & Moore, 1999; Inestrosa et al., 1996; De Ferrari 
et al., 2001), forming stable AChE-Aβ complexes, (Alvarez et al., 1997; Alvarez et al., 
1998) and causing an increase in the neurotoxicity of the Aβ fibrils (Muñoz & Inestrosa, 
1999; Reyes et al., 2004). In addition, AChE activities have also been reported to correlate 
with the density of Aβ deposition in the AD brain (Arendt et al., 1992). Recent 
experiments suggest that during the early stage of AD, Aβ enters the mitochondria 
increasing the generation of free radicals and might induce OS. Aβ and amyloid precursor 
protein (APP) were also reported in the mitochondrial membranes of post-mortem brain 
and found to be responsible for disruption of electron transport chain to cause irreversible 
neurodegeneration and cell damage (Sharma et al., 2019). 
Monoamine oxidase (MAO) is the major metabolic enzyme responsible for the 
deactivation of the monoamine neurotransmitters generating the corresponding aldehyde, 
ammonia, and hydrogen peroxide as metabolic products (Ramsay, 2016). Since MAO 
catalytic activity produces hydrogen peroxide, the increase in MAO B activity in AD and 
Parkinson`s disease (PD) brain tissues is considered to contribute to the initiation of OS 
and the consequent deleterious effects to the cell. Thus, in addition to their ability to 
elevate the levels of monoamines in the brains of AD patients, both MAO A and B 
inhibitors may prevent OS by decreasing the formation of reactive oxygen species 
(Ramsay, 2016; Ramsay & Tipton, 2017). MAO B expression is generally elevated in 
AD (Kennedy et al., 2003), decreasing monoamine levels. Some work proposes that 
MAO B is also suggested to associate with β-secretase, γ-secretase and to regulate 
neuronal Aβ peptide levels (Hroudova et al., 2016; Schedin-Weiss et al., 2017). Elevated 
MAO could be also associated with the formation of neurofibrillary tangles (Hroudova et 
al., 2016). MAO A also influences monoamine levels, particularly serotonin in 
depression, (Bortolato & Shih, 2011). MAO A levels, regulated by genetic and 
environmental factors, including stress, hormonal deregulation and food influences, are 
up or down or unchanged in various brain areas (Naoi et al., 2018). Recent evidence 
suggests that MAO-A generated ROS is involved in quality control signaling in 
mitochondria (Ugun-Klusek et al., 2019; https://doi.org/10.1016/j.redox.2018.10.003). 
4 
 
 
However, the role of MAO A in the trafficking and the health (and hence energy output) 
of mitochondria is still poorly understood. In AD patients, MAO A level changes seem 
to involve multiple mechanisms influencing cell survival (Cai, 2014). Due to the 
multifactorial nature of AD, design strategies have been envisaged for the development 
of different series of multifunctional drugs. In addition to MAO inhibition, multitarget-
directed ligand (MTDL) properties can include brain permeable iron chelation, ChEs 
inhibition, anti-Aβ aggregation, and neuroprotection among other properties (Unzeta et 
al., 2016). 
Previous studies have indicated that the MAO inhibitory activity of several compounds 
is potentiated by cyanide (Davison, 1957; Ramadan et al., 2007). The potentiating effect 
of cyanide can be ascribed to an activation mechanism whereby cyanide assists the 
binding of the inhibitor to the enzyme (Davison, 1957; Juárez-Jiménez et al., 2014). A 
series of carbonitrile-containing aminoheterocycles were examined experimentally and 
computationally to explore the role of nitriles in determining the inhibitory activity 
against MAO. Dicarbonitrile aminofurans were found to be potent, selective inhibitors 
against MAO A (Juárez-Jiménez et al., 2014). An earlier study examined the inhibition 
of MAO B by a series of C4-substituted phthalonitriles and a series of homologs lacking 
the nitrile units (Manley-King et al., 2012). It was found that the nitrile unit was a 
prerequisite for high binding affinity to both MAO A and MAO B. The high binding 
affinities to MAO B were ascribed to the highly polar nature of the nitrile group. 
Modeling studies indicated that the nitrile group interacts with the polar regions in the 
substrate cavity of the MAO B enzyme (Manley-King et al., 2012; Van deer Walt et al., 
2012; Chirkova et al., 2015). The carbonitrile function has also been introduced by other 
research groups in compounds either with the ChEs inhibitory activity (Samadi et al., 
2010; Samadi et al., 2011; Samadi et al., 2012; Samadi et al., 2013) or dual ChEs and 
MAO inhibitory activities (Samadi, Chioua, Bolea et al., 2011).  
Since the nitrile group may raise concerns regarding cyanide release, published 
information on diverse nitrile-containing drugs, research compounds, and in vivo 
metabolism of carbonitrile derivatives was closely examined. Structurally diverse nitrile-
containing pharmaceuticals are prescribed for a variety of medical treatments, for 
example the selective serotonin re-uptake inhibitor and antidepressant drug citalopram, 
the non-purine xanthine oxidase inhibitor for the treatment of hyperuricemia febuxostat, 
the aromatase inhibitor and anticancer agent letrozole, and the non-nucleoside reverse 
transcriptase inhibitors and anti-HIV drug etravirine (Fleming et al., 2010; Jones et al., 
2010). Regarding letrozole and etravirine, both exhibit two nitrile units as does the analog 
of etravirine, rilpivirine (Reznicek et al., 2017). In drug design, aromatic chloride is very 
often replaced by an aromatic nitrile since this exchange can impart desirable properties 
to the resulting molecule particularly when the potency is similar, or even improved. 
Thus, the lipophilicity of the molecule will be significantly reduced along with enhanced 
metabolic stability, higher aqueous solubility and reduced toxicological outcomes (Jones 
et al., 2010). Due to its small size, metabolic stability and ability to act as a hydrogen 
bond acceptor, the nitrile functional group has been incorporated into several 
pharmaceutical agents (Lindsay-Scott & Gallagher, 2017). A quantitative assay involving 
the reaction of nitriles with glutathione and cysteine has been used as a simple in vitro 
screen to assess potential toxicity risk of candidate compounds in drug discovery and 
decide whether to progress with compounds in the absence of radiolabeling studies 
(MacFaul et al., 2009).  
Regarding metabolic stability, the nitrile group is not particularly electrophilic towards 
free nucleophiles, even glutathione (Fleming et al., 2010; MacFaul et al., 2009) and is 
metabolically quite robust (Boyd et al., 2009) unless activated by adjacent electron-
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withdrawing elements (Oballa et al., 2007). Odanacatib, a selective inhibitor of cathepsin 
K, exhibited excellent metabolic stability in hepatocyte incubations across several 
species. In standard incubations (2x106 cells/mL, 20 μM, 2 h), a 96% recovery of the 
parent compound was found in rat hepatocytes and a 98% recovery was obtained in rhesus 
monkey hepatocytes. High recovery (>99%) was observed in both dog and human 
hepatocyte incubations (Gauthier et al., 2008). In most nitrile-containing drugs, the nitrile 
group passes through the body metabolically unaffected. Cimetidine, an H2 receptor 
antagonist, after both oral and intravenous doses in man, is oxidized to the sulfoxide (6-
10%) and hydroxymethyl (4%) metabolites and conjugated to the N-glucuronide (24%), 
presenting unchanged drug (60-70%) (Strong & Spino, 1987). The biotransformation of 
entacapone, a catechol O-methyltransferase inhibitor was studied in experimental animals 
and man by identifying their O-glucuronides in urine and plasma; in rats and dogs, O-
sulfates were also abundant (Wikberg & Vuorela, 1994). Early studies with radiolabelled 
cromakalim, an antihypertensive agent, showed the major urinary metabolites had 
unchanged nitrile groups (Kudoh, 1990; Kudoh et al., 1990). Lersivirine, a non-
nucleoside reverse transcriptase inhibitor, is predominantly cleared by glucuronidation 
and cytochrome P450-mediated oxidation whereas hydrolysis of one of the nitrile 
moieties to form an amide represented less than 8% of the total in plasma (Vourvahis et 
al., 2010). The major urinary and plasma metabolites of verapamil, a phenethylamine 
vasodilator, were the N-dealkylated products which retain the α-
isopropylphenylacetonitrile portion of the molecule (McIlhenny, 1971). 
Release of cyanide from aromatic or fully substituted carbons is not observed (Fleming 
et al., 2010). Rabbits converted 2,6-dichlorobenzonitrile to an extent of approximately 
2% and 23% into 2,6-dichloro-4-hydroxybenzonitrile and 2,6-dichloro-3-
hydroxybenzonitrile, respectively. The hydrolysis of the nitrile group appears to occur to 
a very minor extent. Only insignificant amounts of the amide (<0.01%) and benzoic acid 
(<0.001%) derivatives were found. This was supported by the observation that rabbits did 
not convert 2,6-dichlorobenzamide into the corresponding acid (Wit & van Genderen, 
1966). However, saturated and β,γ-unsaturated aliphatic nitriles are hydroxylated in the 
liver at the α-carbon to form cyanohydrins with subsequent cyanide release (Hideji & 
Kazuo, 1984, 1986). Mandelonitrile, an agent formerly used for the treatment of urinary 
tract infections, bears a H atom and OH group at the α-carbon. The cyanide plus 
thiocyanate excreted by Wistar rats represented 86% of the dose, hippuric acid 
corresponded to 71%, while 13% correlated to mandelic acid (Singh et al., 1985). 
Epoxidation of alkenenitriles and ring opening can potentially liberate cyanide, but 
epoxidation is synthetically difficult (Pryde et al., 1996; Aiai et al., 1995; Miyashita et 
al., 1987) and metabolism at other sites appears more likely to occur (Fleming et al., 
2010). 
Based on the MAO inhibition properties of aminofurans with the carbonitrile group 
(Juárez-Jimenez J. et al., 2014), the present study aimed to identify classes of nitrile-
containing compounds endowed with dual AChE and MAO inhibitory activities, and Aβ 
anti-aggregating properties. In this context, we have carried out the synthesis, biological 
evaluation, and molecular modeling of a number of arylidenepropanedinitriles 
[compounds 16-41, Scheme 1, Tables 1, 7, and Tables S1, S3, S8, and S9 (Supporting 
Information)], [(phenylamino)methylidene]propanedinitriles] [compounds 42-52, 
Scheme 2, Table 2 and Table S6 (Supporting Information)], 4-amino-1-phenyl-1H-
pyrrole-3-carbonitriles [compounds 53-57, Scheme 3, Table 3, and Tables S7, and S10 
(Supporting Information)], and 3-amino-1-phenyl-1H-pyrrole-2,4-dicarbonitriles 
[compounds 58-62, Scheme 3, Tables 3, 7, and Tables S7, and S10 (Supporting 
Information)], (phenylhydrazinylidene)propanedinitriles [compounds 63-67, Scheme 4, 
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Tables 4, 7, and Table S4 (Supporting Information)], 4-arylazo-3,5-diamino-1H-
pyrazoles [compounds 68-72, Scheme 5, Table 5 and Table S5 (Supporting 
Information)], and (E,E)-4-amino-1-aryl-3-cyano-4-methoxy-2-azabutadienes 
(compounds 73-75, Scheme 6, Table 6). 
 
 
2 MATERIALS AND METHODS 
 Materials and methods for Chemistry and Pharmacology are reported in Supporting 
Information. Caution: Storage and safety working conditions regarding malononitrile, 
arylidenemalononitriles and some nitrile-containing chemicals are mentioned in 
Supporting Information. 
 
 
3 RESULTS AND DISCUSSION 
3.1 Chemistry 
 
3.1.1 Synthesis of arylidenepropanedinitri les 
Arylidenepropanedinitriles 3 (compounds 16-41) (Scheme 1) were synthesized by 
straightforward Knoevenagel condensation of the respective aldehyde 1 with 
malononitrile (2) (Gazit et al, 1989). Most compounds are common starting materials or 
intermediates in chemical reactions (Zayed et al., 1991; Marco et al., 2004; Ding & Zhao, 
2010). Interesting results were also made known regarding their capacity to activate cell 
resistance to oxidative stress (Turpaev et al., 2011).  Here we report the MAO and AChE 
inhibitory properties of a few arylidenepropanedinitriles and chemical data of the new 
arylidenepropanedinitriles 31, 34, 35 and 36 (Scheme 1; Figure 1). 
 
 
Scheme 1 here 
 
 
3.1.2 Synthesis of [(phenylamino)methylidene]propanedinitri les 
[(Phenylamino)methylidene]propanedinitriles type 6 (compounds 42-52) (Scheme 2) 
were readily synthesized by the reaction of malononitrile 2 with ethyl orthoformate 4 and 
the respective aniline derivative 5 (Wolfbeis, 1981). The MAO and AChE inhibitory 
activities are reported here as well as the data for the new 
[(phenylamino)methylidene]propanedinitrile derivatives 45, 48, and 52 (Scheme 2; 
Figure 1). 
 
 
Scheme 2 here 
 
 
3.1.3 Synthesis of 4-amino-1-phenyl-1H-pyrrole-3-carbonitri les 
and 3-amino-1-phenyl-1H-pyrrole-2,4-dicarbonitri les 
The syntheses of both 4-amino-1-phenyl-1H-pyrrole-3-carbonitriles (compounds 53-
57) and 3-amino-1-phenyl-1H-pyrrole-2,4-dicarbonitriles (compounds 58-62) are 
represented in Scheme 3 (compounds type 8). These syntheses were based on a Thorpe-
Ziegler cyclization via intermediate 7 using [(phenylamino)methylidene]propanedinitrile 
derivatives 6 as precursors (Scheme 2), an α-halo compound (chloroacetonitrile, 
7 
 
 
chloroacetone, ethyl bromoacetate, α-bromoacetophenone) and triethylamine. 
(Salaheldin et al., 2008; Unverferth et al., 1998; Salaheldin et al., 2010). Pharmacological 
data are reported concerning MAO inhibitory activities of type 8 compounds. 
Additionally, chemical data are addressed to the new compounds 59 and 60 (Scheme 3; 
Figure 1). 
 
Scheme 3 here 
 
 
3.1.4 Synthesis of (phenylhydrazinylidene)propanedinitri les 
Phenylhydrazonomalononitriles 11 (compounds 63-67) (Scheme 4) were prepared by 
diazotization of the appropriate arylamine 9, followed by condensation of the diazonium 
salt 10 with malononitrile (Krystof et al., 2006). Compounds 63 (Krystof et al., 2006), 64 
(Gavlik et al., 2017), 65 (Amer et al., 2004) and 66 (Tsai & Wang, 2005) are reported in 
the literature while (phenylhydrazinylidene) propanedinitrile 67 (Scheme 4) is a new 
compound which is described here for the first time. Pharmacological data are reported 
concerning MAO inhibitory activities of compounds type 11. Additionally, chemical data 
are provided for the new compound 67 (Scheme 4; Figure 1). 
 
Scheme 4 here 
 
 
3.1.5 Synthesis of 4-arylazo-3,5-diamino-1H-pyrazoles 
The 4-arylazo-3,5-diamino-1H-pyrazoles 12 (compounds 68-72) were obtained by 
cyclocondensation of phenylhydrazonomalononitriles 11 (compounds 63-67) with 
hydrazine (Krystof et al., 2006). Compounds 68 (Krystof et al., 2006; Al-Afaleq, 2000; 
Elgemeie et al., 2001), 69 (Al-Afaleq, 2000; Elgemeie et al., 2001), 70 (Huppatz et al., 
1981), and 71 (Zhang et al., 2001) are reported in the literature while diaminopyrazole 72 
(Scheme 5; Figure 1) is described here for the first time.  
 
Scheme 5 here 
 
3.1.6 Synthesis of (E,E)-4-amino-1-aryl-3-cyano-4-methoxy-2-
azabutadienes 
The (E,E)-4-amino-1-aryl-3-cyano-4-methoxy-2-azabutadienes 15 (compounds 73-75) 
(Scheme 6) were synthesized by reaction of benzaldehyde (13: X=H) or its derivatives 
with aminomalononitrile p-toluenesulfonate (14) (Scheme 6) (Gutch et al., 2001). The 
synthesis of compound 73 is reported (Gutch et al., 2001). Compounds 74 and 75 (Scheme 
6) are new. Here we report the chemical data and the MAO inhibitory activities for the 
new compounds 74 and 75 (Scheme 6; Figure 1). 
 
Scheme 6 here 
 
 
Figure 1 represents the chemical structures of all the new compounds (31, 34, 35, 36, 45, 
48, 52, 59, 60, 67, 72, 74, 75). 
 
 
Figure 1 here 
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3.1.7 Diverse pyrazole derivatives (compounds 76-81) (Silva et al., 2010, Silva et 
al., 2011) and (phenoxyalkoxybenzylidenemalononitriles (compounds (81, 82) (Silva et 
al., 2013) were previously synthesized and their AChE inhibitory activities reported. Here 
we describe their inhibitory activities in rat mitochondria (rMAO A and rMAO B) (Table 
S2, Supporting Information). 
 
 
3.2 Pharmacology 
3.2.1 Monoamine oxidase inhibition 
 
Compounds were screened for MAO inhibition using various assays: direct radiometric 
(rat mitochondrial MAO) or spectrophotometric (purified human MAO) assays or 
coupled fluorescent assays (any preparation). Initial screening was performed at fixed 
concentrations (10 or 25 μM) with 2xKM substrates. Where inhibition greater than 70% 
was observed, IC50 values were measured. The IC50 values for selected inhibitors were 
re-evaluated in the coupled assay with horseradish peroxidase, measuring the 
fluorescence of resorufin produced in the presence of 2xKM tyramine as substrate.  
 
Table 1 shows IC50 values for purified human MAO A obtained using the 
spectrophotometic assay with kynuramine as the substrate. For the 
arylidenepropanedinitrile derivatives, an electron-rich substituent (F, Cl, NO2) at the para 
position is detrimental to inhibition, although m-NO2 is tolerated. Methoxy and 
propenyloxy substituents in the para position increase binding (19, 22) but the benzyl 
ring substituent in 23 prevents binding. Changing the core benzyl ring to furan gives better 
inhibition (30, 31 and 32).  
 
Table 1 here 
 
 
 
Only one of the [(phenylamino)methylidene]propanedinitrile derivatives was active, 
presumably due to interactions conferred by the m-NO2 group (49 in Table 2). 
The phenylpyrrole mono- and dicarbonitriles (Table 3) were likewise poor inhibitors 
with only the dicarbonitrile 60 active with an IC50 of 6.2 µM.  
The (phenylhydrazinylidene)propanedinitrile derivatives 63-67 (Table 4) were more 
promising with 5 active compounds. Methyl substitution in 67 was not good but the parent 
compound 65, the p-Cl 66 and di-methoxy 64 derivatives gave IC50 values around 10 μM. 
The best inhibitor in this series was 63, the m-NO2 compound with an IC50 value of 1.65 
μM. 
Switching the dinitrile to a pyrazole group (Table 5) did not improve inhibition. The 
only active compound, the p-Cl derivative 69 was not much changed from the p-Cl 
derivative in the dinitrile series (66 in Table 4). 
Similarly, for the aminomethoxy compounds in Table 6, only one active compound was 
found. The 4-CN derivative 75 gave an IC50 value of 1.92 μM against human MAO A, 
100 times better that the parent compound 73. 
 
Table 2 here 
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Table 3 here 
 
 
 
 
Table 4 here 
 
 
 
Table 5 
 
 
 
Table 6 here 
 
 
Since behavioral tests are performed on rodents, some compounds were also evaluated 
on MAO A and MAO B present in rat liver mitochondria (RLM) as presented in the 
Supplementary Information. Table S1 shows the IC50 values for arylidenepropanedinitrile 
derivatives on RLM, assaying MAO A with [14C]-serotonin (5-HT) and MAO B with 
[14C]-β-phenylethylamine (PEA). Although 16, 20, and 26 were poor inhibitors as in 
purified hMAO A (around 60 μM, Table 1), 20 with two methoxy substituents was a 
better inhibitor than the others in the RLM MAO A assay (IC50 15.9 μM). Compounds 24 
and 25 also gave similar IC50 values against both human and rat MAO A. The RLM study 
allows direct comparison of selectivity between MAO A and B (Table S1). Although both 
19 and 20 inhibit RLM MAO A, the extra m-OCH3 in 20 removed the inhibition of MAO 
B seen with the mono-OCH3 compound (19), making 20 selective for MAO A. The m-
NO2 derivative (25) is the best non-selective inhibitor of rat MAO, but moving the NO2 
to the para position (24) makes the compound selective for MAO B. Thus, in rat 25 is 
non-selective whereas 20 is MAO A-selective and 24 is B-selective, suggesting that 
discrimination is based on fine steric or electronic interaction in the active sites. None of 
the pyrazole derivatives (compounds 76-81) and the 
phenoxyalkoxybenzylidenemalononitriles (compounds 81, 82) shown in Table S2 
inhibited rMAO in RLM, but the arylidenepropanedinitrile series in Table S3 revealed 
some inhibition. rMAO A was inhibited by the rigid 40 (IC50 = 18 μM) but more 
effectively by the flexible structures in 22 (3.5 μM) and 30 (0.72 μM). These compounds 
also inhibited rMAO B. The most effective on rMAO B were 23 (1.2 μM), and 28 (7.5 
μM), neither of which inhibited MAO A in rat mitochondria.  
Returning to human MAO, the inhibition of MAO A and MAO B was compared for 
several compound series using the coupled assay for hydrogen peroxide production. Table 
S4 reports the % inhibition at 25 μM and IC50 values for 
(phenylhydrazinylidene)propanedinitrile compounds.  Although di-methoxy substitution 
in 64 gives equal inhibition of MAO A (IC50 = 22 μM) and MAO B (25 μM), the m-NO2 
(63) is 10 times better against MAO B (0.52 μM) than against MAO A (5.8 μM). In the 
same range (IC50 values less than 10 μM), but non-selective, are 68-72 in Table S5, 
showing that the diaminopyrazole ring gives better inhibition than the dinitriles (63-67 in 
Table S4). Table S6 confirms poor inhibition of human MAO by 
[(phenylamino)methylidene]propanedinitriles with none inhibiting MAO A and only two 
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inhibiting MAO B (45 at 4.27 μM and 52 at 1.66 μM). Table S7 shows that the 4-amino-
1-phenyl-1H-pyrrole-3-carbonitriles did not inhibit human MAO B, but some of the 
dicarbonitriles inhibited by about 50% at 25 μM. Dicarbonitrile 60 did not inhibit MAO 
B but was the only compound in Table S7 that inhibited MAO A (44%). Table S8 
identified two arylidenepropanedinitriles that almost completely inhibited MAO A at 25 
μM, namely 31 and 32 that share a furan linker. 
Some compounds were also screened for inhibition of AChE (commercially cloned and 
purified electric eel AChE) at 10 μM and 5 μM (arylidenepropanedinitriles in Table S9 
and phenylpyrrole aminocarbonitriles in Table S10). Only arylidenepropanedinitrile 37 
(58% at 5 μM) and the phenylpyrrole-aminodicarbonitrile 62 (69% at 10 μM) gave 
inhibition. Otherwise these series were not inhibitory towards AChE. 
 
Thus, compound 31 presents a lead for trifunctional inhibition against MAO A, MAO B 
and AChE (Table 7), while 32 offers a lead for selective MAO A inhibition coupled to 
AChE inhibition. 
 
 
Table 7 here 
 
 
After the primary screening in Tables 1-6 and Tables S1-S10 in Supplementary 
Information, a set of compounds was re-evaluated against all three human enzyme targets. 
Table 7 summarizes the IC50 values for the human MAO and AChE enzymes with the 
selected set of active compounds. Adding a nitrogen to the linker between the phenyl ring 
and the dicarbonitrile group (25 vs 49) loses MAO A inhibition but adding two nitrogens 
(63) improves inhibition of both MAO A and B and introduces some weak inhibition of 
AChE (IC50 = 44 μM). A furan linker again gives best lead compounds: 31 is a good 
inhibitor of both MAO A (0.34 μM) and MAO B (0.26 μM), whereas the trifluoro 
derivative (32) is 100-fold selective for MAO A (0.12 μM vs 15 μM for MAO B). Both 
31 and 32 show some inhibition of AChE (IC50 values of 52 and 48 μM, respectively), so 
are lead compounds to optimize for multi-target activity.  
 
3.2.2. Thioflavin T (ThT) assay to study Aβ aggregation  
For this assay four arylidenepropanedinitriles (31, 32, 33, 37), two 
(phenylhydrazinylidene)propanedinitriles (63, 65), and one representative of (E,E)-4-
amino-1-aryl-3-cyano-4-methoxy-2-azabutadienes (75) were chosen. The capacity of 
these compounds to inhibit the formation of Aβ1-42 fibrils (generated as described in 
Experimental section (Supporting Information) was evaluated using the thioflavin T 
(ThT) fluorescence assay. This assay measures changes in fluorescence intensity of ThT 
upon binding to amyloid fibrils (Le Vine, 1999; Sulatskaya et al., 2012). 
 
Figure 2 here 
 
 
As can be seen in Figure 2, different concentrations (20, 40 and 60 µM) of compounds 
31 (p-OCH3 electron donating group and a m-Cl electron withdrawing group) and 32 (m-
CF3 strong electron withdrawing group) slightly inhibited the formation of Aβ1-42 fibrils, 
by about 25% and an insignificant 15%, respectively.  
The pyrrole derivatives 33 and 37 (Figure 2) differed only in the C5-CN electron 
withdrawing group in 37. Both compounds were ineffective in disaggregating Aβ1-42 
fibrils formation, being less adequate than 31 and 32 (Figure 2).  
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By contrast, compounds 63 and 65 (Figure 3), which differ only in the m-NO2 electron 
withdrawing group present in 63, were able to disaggregate Aβ1-42 fibrils. The most 
effective was 63 (inhibitor effect of 50-60%, depending on the concentration), whereas 
65 (Figure 3), and 75 (Figure 3) (p<0.05) inhibited Aβ aggregation only at high 
concentrations (40 and 60 µM). 
 
 
Figure 3 here 
 
 
3.2.3 Computational chemistry studies 
3.2.2.1 Docking studies on monoamine oxidases 
 
For our study we chose the derivatives 25, 30, 31, 32, 49, 63, and 65. From these 
compounds only 49, 63 and 65 form tautomers with the most probable ones shown in 
Figure 4. The binding energies values obtained for individual structures with MAO A and 
MAO B are represented in Table 8. 
 
Figure 4 here 
 
 
 
 
 
Table 8 here 
 
 
 
 
The analysis of the inhibitor locations in the MAO A model provided several common 
features. If present, it is the nitro group which appears to be responsible for the interaction 
of the active derivatives (Figure 5). The comparison of the structurally similar compounds 
49, 63 and 65 showed that two inhibitors (49 and 63) directed the nitro group towards 
FAD, whereas for 65 (no nitro group) the dicarbonitrile group is directed towards FAD. 
 
 
Figure 5 here 
 
 
 
The main type of the interaction between the active inhibitor and FAD is a cation–π 
relationship, which is a kind of electrostatic interrelation (cation–quadrupol). Positive 
charge is located at nitrogen of nitro group and the π orbital is located at FAD; partial (but 
much lower) positive charge is located on the central carbon connected to the dicyano 
group (Figure 6). The value of the positive charge is also affected by other substituents, 
e.g. for 49 the atomic charge N (nitro) is diminished to 0.713 (Figure 7). 
 
 
Figure 6 here 
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Figure 7 here 
 
 
 
These specific features impacted the values of total binding energies (Table 8), which 
were higher for compound 63 due to a shorter distance from FAD (3.5Å for 63 and 3.7Å 
for 49) as well as two additional interactions more (cation-π interaction with Tyr407 and 
hydrophobic interaction with Tyr444).  
Another important factor affecting the ligand interaction is the presence and location of 
water molecules. The original ligand harmine has water molecules near it in the binding 
site. The docking procedure including water molecules is rather peculiar, so water was 
included after docking in the procedure of complex optimization. The addition of water 
was important to explain the lower activity of 30 (Figure S1). Although it interacts with 
Gln215, binding of 30 is hindered by more effective interaction of water molecule 
(HOH5342) with FAD.  
Inspecting the binding modes of the strongest MAO A inhibitors 31 and 32 (Figure 8), 
it can be seen that the benzene ring of 31 is situated near the aromatic cleft of TYR 407 
and TYR 444, but the malononitrile group of 32 is more deeply immersed into this region, 
at a distance of 2.99 Å from C10a of flavin. Docking and optimization studies provided 
two preferred orientations for both compounds: one with the malononitrile group near 
flavin and the second one with opposite direction. It seems that it is the substitution on 
the benzene ring which specifies the orientation of arylidenepropanedinitriles 31 and 32 
as well as that for the (phenylhydrazinylidene)propanedinitriles 63, 65 and 
[(phenylamino)methylidene]propanedinitrile 49. Nitro and methoxy groups in positions 
meta and para of the benzene ring create sufficiently strong interactions with flavin or 
the aromatic cleft of the catalytic center while trifluoromethyl or no substitution permits 
the molecule to turn malononitrile group towards flavin. The abundant numbers of 
attractive interactions of 31 and 32 are reflected in values of binding energy (Table 8).  
The inhibition activities of compounds 31 and 32 in MAO B were different from those 
in MAO A. The activity of 31 stayed almost the same, while IC50 for 32 decreased in two 
orders from 0.12 µM to 15.2 µM. (Table 7). Docking calculations and subsequent 
optimization revealed the opposite orientation of the molecule 31 in MAO B compared 
with MAO A (Figures 8 and 9).  
 
 
Figure 8 
 
 
 
Figure 9 here 
 
 
 
Both compounds interact with the gating residues Ile199 and Tyr326, which separate 
entrance and substrate cavities in MAO B (Milczek et al., 2011). However, in MAO B, 
the position of the conjugated malononitrile groups in the vicinity of the aromatic cleft 
was strengthened by close contact of one cyano nitrogen with hydroxyl group of Cys172 
for 31 and by the interaction with internal water near FAD for 32. Due to the surrounding 
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residues and water, the furan ring and the malononitrile group of 32 are visibly turned 
against the substituted benzene ring (sum of both deviations is 44°). This fact breaks the 
conjugation in 32 and, finally, penalizes the position of 32 in MAO B when compared 
with 31, which is turned less (22°).  
The water molecules can provide additional interactions for ligand and stabilize or 
destabilize its position. Water found in the binding of 32 in MAO B pocket is positionally 
similar to the water molecule participating in catalysis. So far, there has been no structural 
work on MAO to show the positioning of ligands with the malononitrile group in the 
active site. 
A similar binding mode can be observed for 63. This compound is depicted in Figure 
S2 for the binding sites of MAO A and MAO B. The nitro group of 63 adjacent to FAD 
in both types of MAO is preferred, although for both enzymes reverse positions also exist 
(Figure S3). but with lower values of binding energy. (The differences in values of 
binding energy were 20.5 kJ/mol for MAO A and 4.3 kJ/mol for MAO B.). Compound 
63 is bound in MAO A with Tyr407 by π-π and cation- π interaction and with FAD by 
cation-π interaction with distance 4.1 Å. The position is stabilized by H-bonds with 
Phe208 and one surrounding water molecule, as well as a hydrophobic interaction with 
Gln215. However, both H-bonds make the position less energetically favorable due to the 
twisting of malononitrile group. Interaction with Phe208 in MAO A or Ile199 in MAO B 
has been related to selectivity of compounds either in the role of inhibitors (Morón et al., 
2000) or as substrates (Tsugeno & Ito, 1997). The stronger inhibition of MAO B with 63 
was visualised as a firm position of nitro group between Tyr398 and Tyr435, H-bond with 
Tyr188 and π-π edge-to-edge interaction with FAD (distance 3.7 Å). The malononitrile 
group is held by a single H-bond with a water molecule occurring in the cavity. The 
resulting position keeps the whole molecule in one plane, contributing thus to the overall 
benefit of this mode of interaction.  
For further work, the affinity of 63 towards MAO B could be enhanced by a proper 
substitution in 2 or 3 position from the nitro group. An interesting study would be made 
with a thiol substitution, as in the proximity of these two places there is Cys172, which 
could thus create a disulfide bond with the ligand. Another possibility would be to 
introduce a benzyl or phenyl group in position 1, to obtain the π-π interaction with Tyr435. 
 
 
3.2.2.2 Docking studies on acetylcholinesterase 
 
Docking and optimization calculations were performed to determine the binding mode 
of ligands to AChE for compounds 32 (Table S9), 37 (Table S9, Figure S4), 62 
(Salaheldin et al., 2008) (Table S10), 82 [IC50 (AChE = 6.0 ± 0.5 µM)] (Silva et al. 2013), 
(Table S2, Figures 10, 11), and 83 [IC50 (AChE = 2.1 ± 0.5 µM)] (Silva et al. 2013) (Table 
S2, Figures 10, 11). In the figures, all the compounds are rendered as balls and sticks. The 
side chains conformations of the mobile residues are illustrated in the same color (light 
blue) as the ligand.  Different subsites of the active site are colored as follows: catalytic 
triad (CT) in green, oxyanion hole (OH) in pink, anionic subsite (AS) in orange except 
Trp86, acyl binding pocket (ABP) in yellow, peripheral anionic site (PAS) in cyan and 
the non-active site residues in grey. Hydrogen bonds are represented as yellow dashed 
lines, π-π interactions as red lines, π-cation interactions as blue lines and hydrophobic 
contacts as green ones. 
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Figure 10 here 
 
 
 
 
 
 
 
 
Figure 11 here 
 
 
 
 
 
Table S12 summarizes the values of binding energy (Ebin) together with the inhibition 
activities of the chosen compounds.  The binding energy values for 32 and 62 correspond 
to their lower activities, but 37 should be as strong inhibitor as 82 and 83 according to 
Ebin value. This compound is immersed in the ligand cavity with both malononitrile and 
cyano groups (Figure S4) bound to Trp86 (π-π interaction), Phe297 (hydrophobic) and 
Glu204 (H-bond). According to these interactions, 37 should be much stronger inhibitor 
than it was measured. The reason for its lower activity could be found in the value of the 
solvation energy (Table S11), which is very low and thus represents quite a big value of 
desolvation penalty in total ligand binding. 
Compounds 82 and 83 contain long aliphatic chains and, for both, the malononitrile 
group represents the hydrophilic part in a generally hydrophobic molecule (Figure 12), 
which can be observed also in values of solvation energy (Table S11). The length of the 
aliphatic chain fits in the cavity of hAChE more comfortable for 83 than for 82 (Figure 
10). Both compounds are anchored to the cavity by strong interaction between 
malononitrile group and Trp236 from the PAS region. Malononitrile groups, directed to 
the outer space, are also bound with surrounding water molecules (Figure 11). The 
compounds fill major parts of the ligand cavity, 83 more than 82. (Figure 11). 
 
 
 
 
 
Figure 12 here 
 
 
 
 
 
 
 
4 CONCLUSIONS 
 
In this paper we have reported the synthesis and biological evaluation of 83 compounds, 
13 of which are new. Based on the MAO inhibition properties of the carbonitrile group 
we carried out a systematic exploration to discover new classes of nitrile-containing 
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compounds endowed with dual AChE and MAO inhibitory activities, and Aβ anti-
aggregating properties. Thus, arylidenepropanedinitriles, 
[(phenylamino)methylidene]propanedinitriles], 4-amino-1-phenyl-1H-pyrrole-3-
carbonitriles, 3-amino-1-phenyl-1H-pyrrole-2,4-dicarbonitriles, 
(phenylhydrazinylidene)propanedinitriles, 4-arylazo-3,5-diamino-1H-pyrazoles and 
(E,E)-4-amino-1-aryl-3-cyano-4-methoxy-2-azabutadienes were synthesized and 
assessed. 
From in vitro screening, compound 31 presents the best lead for trifunctional inhibition 
against MAO A, MAO B and AChE (Table 7), while 32 offers a lead for selective MAO 
A inhibition coupled to AChE inhibition. 
Computational analysis of the binding modes of the compounds demonstrated several 
characteristic features. The malononitrile group, when not overcome by more attractive 
groups as nitro or methoxy groups, can find an advantageous position with the aromatic 
cleft and FAD of MAO A or MAO B.  The total binding energy can be handicapped by 
an internal penalty caused by twisting of ligand molecule and subsequent disruption of 
the conjugation as happens in 32 with MAO B compared to the conjugated 31. 
Conjugation is also important for AChE. In addition, the hydrophilic character of 
malononitrile allows this group to be in close contact with the water environment in the 
more open binding pocket of AChE, as seen for 83 in AChE.  
Although the effect of 31 and 32 against Aβ1-42 was very weak, the effect of the other 
compounds was quite comparable to the action observed for resveratrol (20 µM), used as 
a reference disaggregating compound (Silva et al. 2013). Overall, the data indicated that 
compounds 63, 65 and 75 (Figure 3) were able to disaggregate Aβ1-42 fibrils. The most 
effective was 63, a (phenylhydrazinylidene)propanedinitrile derivative that also inhibited 
MAO A at micromolar concentration, making it a potential lead for Alzheimer`s disease 
application. 
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TABLE 1  IC50 values (µM) for inhibition of human MAO A by arylidenepropanedinitriles 16-41 
 
IC50 values were determined spectrophotometrically with kynuramine as substrate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound X, Y, Z hMAO A 
IC50 (µM) 
 
 
 
 
 
 
 
16  X,Y,Z=H 
17  X,Y=H; Z=CH3 
18  X=CH3; Y,Z=H 
19  X,Y=H; Z=OCH3 
20  X=H; Y,Z=OCH3 
21  X,Y,Z=OCH3 
22  X,Y=H; Z=OCH2CHCH2 
23  X,Y=H; Z=OCH2Ph 
24  X,Y=H; Z=NO2 
25  X,Z=H; Y=NO2 
26  X,Y=H; Z=Cl 
27  X,Y=H; Z=F 
28  X,Y=H; Z=CN 
29  X=CN; Y,Z=H 
  60.7 ±11.4 
>100 
  71.3 ±362 
  21.4 ±2.70 
  58.0 ±12.0 
288.0 ±33.6 
  11.3 ±1.08 
>100 
>100 
   9.05 ± 0.091 
   68.9 ± 4.70 
 258.0±68.8 
   27.4±7.40 
 >100 
 
 
 
 
30  X,Y=H; Z=NO2 
31  X=H; Y=Cl; Z=OCH3 
32  X,Z=H; Y=CF3 
 
 
  15.7±1.87 
  2.67±0.274 
  1.43±0.265 
 
 
 
 
33  X,Y,Z=H 
34  X,Z=H; Y=OCH2Ph 
35  X=Br; Y,Z=H 
36  X,Y=H; Z=CN 
37  X,Z=H; Y=CN 
 
 
  43.4±10.6 
  71.7±43.4 
  15.9±4.07 
  66.6±59.2 
 166.0±27.2 
 
 
 
 
38 
 
 
  27.2±4.47 
 
 
 
39 
 
172.0±28.6 
 
 
 
40 
 
  13.7±1.06 
 
 
 
 
 
41 
 
 
>100 
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TABLE 2  IC50 values (µM) for inhibition of human MAO A 
by [(phenylamino)methylidene]propanedinitriles 42-52. 
 
 
 
X, Y, Z,W,Q hMAO A 
IC50 (µM) 
42  X,Y,Z,Q,W=H >100 
43  X=CH3; Y,Z,Q,W=H >100 
44  X,Q=CH3; Y,Z,W=H >100 
45  X,Z,Q=CH3; Y,W=H 78.6±70.1 
46  X,Z,Q=H; Y,W=CH3 109±72.6 
47  X,W,Q=H; Y,Z=CH3 108±24.0 
48  X,W,Q=H; Y,Z=OCH3 >100 
49  X,Z,W,Q=H; Y=NO2 9.65±1.36 
50  X,Y,W,Q=H; Z=Cl >100 
51  X,Z=Cl; Y,W,Q=H >100 
52  X,Q=CH3; Y,W=H; Z=Br 197±90.7 
IC50 values were determined spectrophotometrically with kynuramine as substrate. 
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TABLE 3  IC50 values (µM) for inhibition of human MAO A by 4-amino-1-phenyl-1H-pyrrole-3-
carbonitriles 53-57 and 3-amino-1-phenyl-1H-pyrrole-2,4-dicarbonitriles 58-62. 
 
X, Y, Z,W,Q,R hMAO A 
IC50 (µM) 
53  X,Y,Z,W,Q=H; R=CO2Et 36.2±6.91 
54  X,Y,Z,W,Q=H; R=COCH3 >100 
55  X,Y,W,Q=H; Z=Cl; R=CO2Et 92.5±18.9 
56  X,Y,W,Q=H; Z=Cl; R=COCH3 >100 
57  X,Y,W,Q=H; Z=OCH3; R=CO2Et >100 
58  X,Y,Z,W,Q=H; R=CN 1464±513 
59  X,W,Q=H; Y,Z=CH3; R=CN 113±17.4 
60  X,Z,Q=H; Y,W=CH3; R=CN 6.21±4.69 
61  X,Y,W,Q=H; Z=Cl; R=CN 241±36.3 
62  X,Y,W,Q=H; Z=OCH3; R=CN >100 
IC50 values were determined spectrophotometrically with kynuramine as substrate. 
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TABLE 4  IC50 values (µM) for inhibition of human MAO A by 
(phenylhydrazinylidene)propanedinitriles 63-67. 
 
 
X, Y, Z hMAO A 
IC50 (µM) 
63  X,Z=H; Y=NO2 
64  X=H; Y,Z=OCH3 
65  X,Y,Z=H 
1.65±0.17 
10.7±3.79 
9.57±3.60 
66  X,Y=H; Z=Cl 11.4±6.79 
67  X=H; Y,Z=CH3 43.5±18.5 
IC50 values were determined spectrophotometrically with kynuramine as substrate. 
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TABLE 5  IC50 values (µM) for inhibition human MAO A by 4-arylazo-3,5-diamino-1H-pyrazoles 68-
72. 
 
 
 
X, Y, Z hMAO A 
IC50 (µM) 
68  X,Y,Z=H 
69  X,Y=H; Z=Cl 
70  X,Z=H; Y=NO2 
>100 
19.7±17.9 
420±250 
71  X=H; Y,Z=OCH3 >100 
72  X=H; Y,Z=CH3 >100 
IC50 values were determined spectrophotometrically with kynuramine as substrate. 
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TABLE 6  IC50 values (µM) for inhibition of human MAO A by (E,E)-4-amino-1-aryl-3-cyano-4-
methoxy-2-azabutadienes 73-75. 
 
 
 
X, Y, Z hMAO A 
IC50 (µM) 
73  X,Y,Z=H 251±95.1 
74  X,Y=H; Z=OCH2CHCH2 113±130 
75  X,Y=H; Z=CN   1.92±0.927 
IC50 values were determined spectrophotometrically with kynuramine as substrate. 
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Table 7  IC50 values (µM) for inhibition of human MAO A, MAO B and AChE by selected compounds 
(25, 31, 32, 49, 60, 63, 65, 75). 
 
Comp.  
 
Structure 
IC50 (µM) after 5 min preincubation 
hMAO A hMAO B hAChE 
 
25 
 
 
 
44.7±20.6 
 
24.6±9.4 
 
 
 
31 
 
0.34±0.05 
 
0.26±0.11 
 
52±8 
 
32 
 
 
0.12±0.03 
 
15.2±5.3 
 
48±2 
 
49 
 
 
 
>100 
 
 
21.5±2.5 
 
 
 
 
 
60 
 
 
 
 
 (>100) 
 
 
 (>100) 
 
 
 
 
 
 
63 
 
 
 
 
12.2±4.1 
 
 
3.80±0.31 
 
 
44±5 
  
65 
 
 
 
22.9±1.5 
 
 
<10% 
at 25 µM 
 
 
<10% 
at 100 µM 
 
 
75 
 
3.41±0.83 
 
3.45±0.52 
 
71±10 
 
ASS234† 
 
 
 
0.053±0.004* 
 
1.2±0.1‡ 
 
0.23±0.02 
IC50 values were determined in the coupled assay with tyramine (2xKM). 
† Bolea et al., 2011. 
‡ Without preincubation (i.e., reversible binding) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8  IC50 values and binding energies Ebin towards 
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hMAO A for 25, 30, 49, 63, 65, and harmine. 
Comp. Structure MAO A 
IC50 (µM) 
Ebin 
(kJ/mol) 
 
 
25 
 
 
 
9.05 ±0.091 
 
 
321.6 
    
 
30  
 
15.7 ±1.87 
 
338.3 
    
31 
 
0.34 ±0.05 368.2 
    
32 
 
 
0.12±0.03 377.6 
    
 
49 
 
 
9.65±1.36 
 
323.6 
    
 
63 
 
 
1.65±0.17 
 
346.7 
 
65 
 
 
 
9.57±3.60 
 
272.7 
 
Harmine 
 
  
5-17 nM 
 
395.6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure Legends 
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SCHEME 1  General procedure for the Knoevenagel condensation reaction regarding the syntheses of 
arylidenepropanedinitriles of type 3 (compounds 16-41, Table 1) and the new compounds 31, 34, 35 and 
36. 
 
 
 
SCHEME 2  General procedure for the syntheses of [(phenylamino)methylidene]propanedinitriles of type 
6 (compounds 42-52, Table 2) and the new compounds 45, 48 and 52. 
 
 
 
SCHEME 3  General procedure for the syntheses of both 4-amino-1-phenyl-1H-pyrrole-3-carbonitriles 
and 3-amino-1-phenyl-1H-pyrrole-2,4-dicarbonitriles of type 8 (compounds 53-62, Table 3) and the new 
compounds 59, 60. 
 
 
 
SCHEME 4  General procedure for the syntheses of (phenylhydrazinylidene)propanedinitriles of type 11 
(compounds 63-67, Table 4) and the new compound 67. 
 
 
 
SCHEME 5  General procedure for the syntheses of 4-arylazo-3,5-diamino-1H-pyrazoles of type 12 
(compounds 68-72, Table 5) and the new compound 72. 
 
 
 
SCHEME 6  General procedure for the syntheses of (E,E)-4-amino-1-aryl-3-cyano-4-methoxy-2-
azabutadienes of type 15 (compounds 73-75, Table 6) and the new compounds 74 and 75. 
 
 
 
FIGURE 1. The structures of all the new arylidenepropanedinitriles (31, 34, 35, 36), the 
[(phenylamino)methylidene]propanedinitriles (45, 48, 52), the 3-amino-1-phenyl-1H-pyrrole-2,4-
dicarbonitriles (59, 60), the (phenylhydrazinylidene)propanedinitrile 67, the 4-arylazo-3,5-diamino-1H-
pyrazole 72, and the (E,E)-4-amino-1-aryl-3-cyano-4-methoxy-2-azabutadienes 74 and 75. 
 
 
 
FIGURE 2  Potential disaggregating effect of 31, 32, 33 and 37 on Aβ1-42 fibrils. Different concentrations 
(20, 40 and 60 µM) of compounds were added to Aβ1-42 samples (pre-incubated at 37ºC for 24 h) and 
incubated at 37ºC for an extra 24 h. The levels of fibrils were evaluated by the intensity of fluorescence of 
ThT. The fluorescence of fibrillary Aβ1-42 (fib), which was incubated at 37ºC for a total time of 48 h, was 
also measured; and the fluorescence of other experimental conditions were indicated as arbitrary units (a.u.) 
related to Aβ1-42. The fluorescence of Aβ1-42 fresh solution (N-fib) was also measured as reference. Data are 
mean±SEM of 3-4 independent experiments.  
 
 
 
FIGURE 3  Potential disaggregating effect of 63, 65 and 75 on Aβ1-42 fibrils. Different concentrations (20, 
40 and 60 µM) of compound were added to Aβ1-42 samples (pre-incubated at 37ºC for 24 h) and for another 
24 h incubation period at 37ºC. The levels of fibrils were evaluated by the intensity of fluorescence of ThT. 
The fluorescence of fibrillary Aβ1-42 (fib), which was incubated at 37ºC for a total time of 48 h, was also 
measured; and the fluorescence of other experimental conditions were indicated as arbitrary units related 
to Aβ1-42. The fluorescence of Aβ1-42 fresh solution (N-fib) and of Aβ1-42 incubated with resveratrol (20 µM 
res), a known anti-aggregating compound, were also measured as reference. Data are mean±SEM of 3-4 
independent experiments. p0.05 statistical different from Aβ1-42 fib. 
 
FIGURE 4  Most probable tautomers of compounds 49, 63 and 65. 
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FIGURE 5  Comparison of the location of 49 (magenta), 63 (element color) and 65 (green) in the proximity 
of FAD. 
 
 
 
FIGURE 6  Charge distribution of compound 63. 
 
 
 
FIGURE 7  Charge distribution of compound 49. 
 
 
 
FIGURE 8  Interactions of 31 and 32 with MAO A. 
 
 
 
FIGURE 9  Interactions of 31 and 32 with MAO B. 
 
 
 
FIGURE 10  Binding mode of 82 and 83 at the active site of hAChE. 
 
 
 
FIGURE 11  Overall view of 82 (blue, up) and 83 (down) immersed in hAChE protein (4M0F PDB 
model) viewed through the gorge of the protein surface. Red circles represent water molecules. 
 
 
 
FIGURE 12  Lipophilic potential on the surface of 83. Blue – hydrophilic values, yellow – hydrophobic.  
 
















